Novotech Korea (CEO John Russell Moller) announced that it will participate in ‘BIO KOREA 5’, which will be held at COEX in Seoul for three days from Wednesday, May 10th to Friday, May 12th.
Novotech Korea is the Korean branch of Novotech, a global company that provides CRO services mainly in the Asia Pacific region. The company explains that they contribute to the development of new drugs by having various companies in the bio-tech field as customers, and are currently conducting business with more than 34 employees in 3,000 offices around the world.
These companies have their own research institutes and phase 1 clinical trial facilities, and have expertise in drug development consulting and FDA regulatory response, participating in more than 1 clinical projects, including all clinical trials from phase 4 to phase 5,000 and bioequivalence tests. . In addition, we are demonstrating our professional capabilities in drug development consulting related to the clinical trial design (IND) package, which is the entire process of conducting clinical trials.
Novotech Korea will participate in BIO KOREA 2023 and introduce the services currently provided by its Korean branch. The plan is to attract additional domestic customers by supporting a wide range of clinical services and regulatory expertise and introducing the excellence of services that provide scientific clinical statistics and data.
An official said, “Last year, our company was selected as the ‘Asia-Pacific Clinical Trial Consignment Organization of the Year Award’ by the Frost & Sullivan Institute, achieving the award for four consecutive years. In addition, we have received awards from authoritative institutions and organizations. “We have highly evaluated the excellence of our systems and services,” he explained. “This is proof that we have been providing faster and more efficient services to our customers while supporting global clinical trials.”
He added, “Our company, which can support optimized clinical trial services in countries around the world, including Asia-Pacific, the United States, and Europe, will be a reliable helper in spreading the capabilities and capabilities of each customer around the world.”
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th this year, is hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Since 2006, BIO KOREA, which has been striving to promote the global status and continuous growth of the Korean health industry, has been strengthening its position as Korea’s representative bio-health international convention with world-renowned scholars and business experts participating every year. BIO KOREA 2023, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, offers various programs such as conferences, business partnering, exhibitions, and invest fairs. It goes on.